Clinical Research Papers:
Association of FGFR3 and FGFR4 gene polymorphisms with breast cancer in Chinese women of Heilongjiang province
Metrics: PDF 1702 views | HTML 1987 views | ?
Yongdong Jiang1, Shanshan Sun1, Wei Wei1, Yanlv Ren1, Jing Liu2 and Da Pang1
1 Department of Breast Surgery, The Third Affiliated Hospital, Harbin Medical University, Harbin, China
2 Department of Anesthesiology, The Second Affiliated Hospital, Harbin Medical University, Harbin, China
Da Pang, email:
Jing Liu, email:
Keywords: breast cancer, FGFR, polymorphism, genetic susceptibility, Chinese
Received: July 05, 2015 Accepted: August 22, 2015 Published: September 27, 2015
Background: The fibroblast growth factor (FGF) receptor pathway is activated in many tumors. FGFR2 has been identified as a breast cancer susceptibility gene. Common variation in other FGF receptors might also affect breast cancer risk. We carried out a case-control study to investigate associations of variants in FGFR3 and FGFR4 with breast cancer in women from Heilongjiang Province.
Methods: SNP rs2234909 and rs3135848 in FGFR3 and rs1966265 and rs351855 in FGFR4 were successfully genotyped in 747 breast cancer patients and 716 healthy controls using the SNaPshot method. The associations between SNPs and breast cancer were examined by logistic regression. The associations between SNPs and disease characteristics were examined by chi-square tests or one-way ANOVA as needed.
Results: The minor alleles of rs1966265 and rs351855 in FGFR4 were strongly associated with breast cancer in the population, with odds ratios of 1.335 (95%CI = 1.154-1.545) and 1.364 (95%CI = 1.177-1.580), respectively. However, no significant associations were detected between other SNPs and breast cancer. Analyses of the disease characteristics showed that SNP rs351855 was associated with lymph-node-positive breast cancer with a dose-dependent effect of the minor allele (P = 0.008).
Conclusions: SNPs rs1966265 and rs351855 in FGFR4 were associated with breast cancer in a northern Chinese population.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.